Wells Fargo’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-153,804
| Closed | -$10.5M | – | 7942 |
|
|
2022
Q3 | $10.5M | Sell |
153,804
-111,562
| -42% | -$6.15M | ﹤0.01% | 1495 |
|
|
2022
Q2 | $8.48M | Sell |
265,366
-23,718
| -8% | -$694K | ﹤0.01% | 1683 |
|
|
2022
Q1 | $10M | Buy |
289,084
+128,489
| +80% | +$3.84M | ﹤0.01% | 1831 |
|
|
2021
Q4 | $4.7M | Buy |
160,595
+51,601
| +47% | +$1.6M | ﹤0.01% | 2635 |
|
|
2021
Q3 | $2.78M | Buy |
108,994
+42,165
| +63% | +$1.24M | ﹤0.01% | 3390 |
|
|
2021
Q2 | $2.34M | Sell |
66,829
-16,940
| -20% | -$661K | ﹤0.01% | 3547 |
|
|
2021
Q1 | $3.41M | Sell |
83,769
-82,065
| -49% | -$3.77M | ﹤0.01% | 3213 |
|
|
2020
Q4 | $7.18M | Buy |
165,834
+27,841
| +20% | +$1.37M | ﹤0.01% | 2392 |
|
|
2020
Q3 | $7.61M | Buy |
137,993
+5,161
| +4% | +$328K | ﹤0.01% | 2113 |
|
|
2020
Q2 | $8.38M | Buy |
132,832
+24,684
| +23% | +$1.69M | ﹤0.01% | 2001 |
|
|
2020
Q1 | $5.53M | Sell |
108,148
-48,540
| -31% | -$3.25M | ﹤0.01% | 2154 |
|
|
2019
Q4 | $12.5M | Sell |
156,688
-19,693
| -11% | -$1.17M | ﹤0.01% | 1805 |
|
|
2019
Q3 | $8.56M | Buy |
176,381
+9,037
| +5% | +$471K | ﹤0.01% | 2063 |
|
|
2019
Q2 | $8.8M | Buy |
167,344
+28,203
| +20% | +$1.62M | ﹤0.01% | 2068 |
|
|
2019
Q1 | $7.37M | Buy |
139,141
+22,525
| +19% | +$1.11M | ﹤0.01% | 2179 |
|
|
2018
Q4 | $4.79M | Buy |
116,616
+9,462
| +9% | +$355K | ﹤0.01% | 2478 |
|
|
2018
Q3 | $4.07M | Sell |
107,154
-3,530
| -3% | -$156K | ﹤0.01% | 2813 |
|
|
2018
Q2 | $5M | Buy |
110,684
+8,570
| +8% | +$390K | ﹤0.01% | 2686 |
|
|
2018
Q1 | $4.93M | Sell |
102,114
-7
| -0% | -$390 | ﹤0.01% | 2627 |
|
|
2017
Q4 | $4.02M | Sell |
102,121
-1,729
| -2% | -$64.6K | ﹤0.01% | 2782 |
|
|
2017
Q3 | $3.22M | Sell |
103,850
-38,240
| -27% | -$1.08M | ﹤0.01% | 2893 |
|
|
2017
Q2 | $3.89M | Buy |
142,090
+21,522
| +18% | +$640K | ﹤0.01% | 2636 |
|
|
2017
Q1 | $4.44M | Buy |
120,568
+24,363
| +25% | +$614K | ﹤0.01% | 2523 |
|
|
2016
Q4 | $1.39M | Buy |
96,205
+75,461
| +364% | +$1.33M | ﹤0.01% | 3446 |
|
|
2016
Q3 | $478K | Buy |
20,744
+7,212
| +53% | +$137K | ﹤0.01% | 3975 |
|
|
2016
Q2 | $225K | Buy |
13,532
+9,570
| +242% | +$193K | ﹤0.01% | 4341 |
|
|
2016
Q1 | $63K | Sell |
3,962
-45
| -1% | -$800 | ﹤0.01% | 5128 |
|
|
2015
Q4 | $129K | Buy |
4,007
+3,979
| +14,211% | +$172K | ﹤0.01% | 4741 |
|
|
2015
Q3 | $1K | Buy |
+28
| New | +$1.32K | ﹤0.01% | 6100 |
|
Other funds holding GBT
Wells Fargo's GBT Position: Q4 2022 in Review
Wells Fargo sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 153,804 shares — an estimated $10.5M sold.
Wells Fargo first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $12.5M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Wells Fargo reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Wells Fargo sold 153,804 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $10.5M.
- Wells Fargo first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Wells Fargo's Global Blood Therapeutics, Inc. position peaked at $12.5M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.